Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC. Rowe SM, et al. Among authors: kerem e. N Engl J Med. 2017 Nov 23;377(21):2024-2035. doi: 10.1056/NEJMoa1709847. Epub 2017 Nov 3. N Engl J Med. 2017. PMID: 29099333 Free PMC article. Clinical Trial.
Aspergillus bronchitis in cystic fibrosis.
Shoseyov D, Brownlee KG, Conway SP, Kerem E. Shoseyov D, et al. Among authors: kerem e. Chest. 2006 Jul;130(1):222-6. doi: 10.1378/chest.130.1.222. Chest. 2006. PMID: 16840406
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M. Kerem E, et al. Among authors: kerem b. Lancet. 2008 Aug 30;372(9640):719-27. doi: 10.1016/S0140-6736(08)61168-X. Epub 2008 Aug 20. Lancet. 2008. PMID: 18722008 Clinical Trial.
New drugs for cystic fibrosis.
Wilschanski M, Kerem E. Wilschanski M, et al. Among authors: kerem e. Expert Opin Investig Drugs. 2011 Sep;20(9):1285-92. doi: 10.1517/13543784.2011.600304. Epub 2011 Jul 11. Expert Opin Investig Drugs. 2011. PMID: 21745147 Review.
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group. Kerem E, et al. Lancet Respir Med. 2014 Jul;2(7):539-47. doi: 10.1016/S2213-2600(14)70100-6. Epub 2014 May 15. Lancet Respir Med. 2014. PMID: 24836205 Free PMC article. Clinical Trial.
Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.
Dagan A, Cohen-Cymberknoh M, Shteinberg M, Levine H, Vilozni D, Bezalel Y, Bar Aluma BE, Sarouk I, Ashkenazi M, Lavie M, Tsabari R, Blau H, Kerem E, Bentur L, Efrati O, Livnat G. Dagan A, et al. Among authors: kerem e. Respir Med. 2017 Oct;131:225-228. doi: 10.1016/j.rmed.2017.08.026. Epub 2017 Sep 1. Respir Med. 2017. PMID: 28947035 Free article.
Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery.
Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T; European CF Society (ECFS) Strategic Planning Task Force on ‘Speeding up access to new 4 drugs for CF’; Amaral MD, de Boeck K, Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T. Davies JC, et al. Among authors: kerem e. J Cyst Fibros. 2019 Sep;18(5):677-684. doi: 10.1016/j.jcf.2019.06.011. Epub 2019 Jul 11. J Cyst Fibros. 2019. PMID: 31303382 Free article.
The future of cystic fibrosis care: a global perspective.
Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, Naehrlich L, Nasr SZ, Oates GR, O'Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. Bell SC, et al. Among authors: kerem e. Lancet Respir Med. 2020 Jan;8(1):65-124. doi: 10.1016/S2213-2600(19)30337-6. Epub 2019 Sep 27. Lancet Respir Med. 2020. PMID: 31570318 Free PMC article. Review.
Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C→T or D1152H Residual Function Mutation.
Kerem E, Cohen-Cymberknoh M, Tsabari R, Wilschanski M, Reiter J, Shoseyov D, Gileles-Hillel A, Pugatsch T, Davies JC, Short C, Saunders C, DeSouza C, Sullivan JC, Doyle JR, Chandarana K, Kinnman N. Kerem E, et al. Ann Am Thorac Soc. 2021 Mar;18(3):433-441. doi: 10.1513/AnnalsATS.202006-659OC. Ann Am Thorac Soc. 2021. PMID: 33095038 Free PMC article. Clinical Trial.
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation.
Oren YS, Irony-Tur Sinai M, Golec A, Barchad-Avitzur O, Mutyam V, Li Y, Hong J, Ozeri-Galai E, Hatton A, Leibson C, Carmel L, Reiter J, Sorscher EJ, Wilton SD, Kerem E, Rowe SM, Sermet-Gaudelus I, Kerem B. Oren YS, et al. Among authors: kerem b, kerem e. J Cyst Fibros. 2021 Sep;20(5):865-875. doi: 10.1016/j.jcf.2021.06.003. Epub 2021 Jul 2. J Cyst Fibros. 2021. PMID: 34226157 Free PMC article.
Spirometry in early childhood in cystic fibrosis patients.
Vilozni D, Bentur L, Efrati O, Minuskin T, Barak A, Szeinberg A, Blau H, Picard E, Kerem E, Yahav Y, Augarten A. Vilozni D, et al. Among authors: kerem e. Chest. 2007 Feb;131(2):356-61. doi: 10.1378/chest.06-1351. Chest. 2007. PMID: 17296633
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.
Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA. Stuart Elborn J, et al. Among authors: kerem e. J Cyst Fibros. 2015 Jul;14(4):507-14. doi: 10.1016/j.jcf.2014.12.013. Epub 2015 Jan 13. J Cyst Fibros. 2015. PMID: 25592656 Free article. Clinical Trial.
The impact of a national population carrier screening program on cystic fibrosis birth rate and age at diagnosis: Implications for newborn screening.
Stafler P, Mei-Zahav M, Wilschanski M, Mussaffi H, Efrati O, Lavie M, Shoseyov D, Cohen-Cymberknoh M, Gur M, Bentur L, Livnat G, Aviram M, Alkrinawi S, Picard E, Prais D, Steuer G, Inbar O, Kerem E, Blau H. Stafler P, et al. Among authors: kerem e. J Cyst Fibros. 2016 Jul;15(4):460-6. doi: 10.1016/j.jcf.2015.08.007. Epub 2015 Sep 16. J Cyst Fibros. 2016. PMID: 26386752 Free article.
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS. Flume PA, et al. Among authors: kerem e. J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4. J Cyst Fibros. 2016. PMID: 26852040 Free article. Clinical Trial.
Clinical impact of Pseudomonas aeruginosa colonization in patients with Primary Ciliary Dyskinesia.
Cohen-Cymberknoh M, Weigert N, Gileles-Hillel A, Breuer O, Simanovsky N, Boon M, De Boeck K, Barbato A, Snijders D, Collura M, Pradal U, Blau H, Mussaffi H, Price M, Bentur L, Gur M, Aviram M, Picard E, Shteinberg M, Livnat G, Rivlin J, Hiller N, Shoseyov D, Amirav I, Kerem E. Cohen-Cymberknoh M, et al. Among authors: kerem e. Respir Med. 2017 Oct;131:241-246. doi: 10.1016/j.rmed.2017.08.028. Epub 2017 Sep 1. Respir Med. 2017. PMID: 28947038 Free article.
Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression.
Cohen-Cymberknoh M, Gindi Reiss B, Reiter J, Lechtzin N, Melo J, Pérez G, Blau H, Mussaffi H, Levine H, Bentur L, Gur M, Livnat G, Perez Miranda J, Polverino E, Blasi F, Aliberti S, Aviram M, Golan Tripto I, Picard E, Novoselsky M, Amsalem H, Hochner Celnikier D, Kerem E, Shteinberg M. Cohen-Cymberknoh M, et al. Among authors: kerem e. J Cyst Fibros. 2021 May;20(3):388-394. doi: 10.1016/j.jcf.2020.09.002. Epub 2020 Sep 9. J Cyst Fibros. 2021. PMID: 32917549 Free article.
How abnormal is the normal? Clinical characteristics of CF patients with normal FEV1.
Cohen-Cymberknoh M, Ben Meir E, Gartner S, Reiter J, Spangenberg A, Garriga L, Eisenstadt I, Israeli T, Tsabari R, Shoseyov D, Gileles-Hillel A, Breuer O, Simanovsky N, Kerem E. Cohen-Cymberknoh M, et al. Among authors: kerem e. Pediatr Pulmonol. 2021 Jul;56(7):2007-2013. doi: 10.1002/ppul.25371. Epub 2021 Mar 26. Pediatr Pulmonol. 2021. PMID: 33704929
Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.
Oren YS, Avizur-Barchad O, Ozeri-Galai E, Elgrabli R, Schirelman MR, Blinder T, Stampfer CD, Ordan M, Laselva O, Cohen-Cymberknoh M, Kerem E, Bear CE, Kerem B. Oren YS, et al. Among authors: kerem b, kerem e. J Cyst Fibros. 2022 Jul;21(4):630-636. doi: 10.1016/j.jcf.2021.12.012. Epub 2021 Dec 28. J Cyst Fibros. 2022. PMID: 34972649 Free article.
The utility of glucose area under the curve from the oral glucose tolerance test as a screening tool for cystic fibrosis-related diabetes.
Gileles-Hillel A, Soesman LH, Miari S, Breuer O, Tsabari R, Elyashar-Earon H, Armoni S, Sprikkelman AB, Reiter J, Zangen D, Lavi E, Kerem E, Cohen-Cymberknoh M. Gileles-Hillel A, et al. Among authors: kerem e. Pediatr Pulmonol. 2022 Nov;57(11):2774-2780. doi: 10.1002/ppul.26100. Epub 2022 Sep 6. Pediatr Pulmonol. 2022. PMID: 35999051
Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.
Sadras I, Kerem E, Livnat G, Sarouk I, Breuer O, Reiter J, Gileles-Hillel A, Inbar O, Cohen M, Gamliel A, Stanleigh N, Gunawardena T, Bartlett C, Gonska T, Moraes T, Eckford PDW, Bear CE, Ratjen F, Kerem B, Wilschanski M, Shteinberg M, Cohen-Cymberknoh M. Sadras I, et al. Among authors: kerem e. J Cyst Fibros. 2023 Nov;22(6):1062-1069. doi: 10.1016/j.jcf.2023.06.001. Epub 2023 Jun 16. J Cyst Fibros. 2023. PMID: 37331863
Cystic fibrosis, pregnancy, and recurrent, acute pancreatitis.
Virgilis D, Rivkin L, Samueloff A, Picard E, Goldberg S, Faber J, Kerem E, Wilschanski M. Virgilis D, et al. Among authors: kerem e. J Pediatr Gastroenterol Nutr. 2003 Apr;36(4):486-8. doi: 10.1097/00005176-200304000-00013. J Pediatr Gastroenterol Nutr. 2003. PMID: 12658041 No abstract available.
Atypical CF and CF related diseases.
Kerem E. Kerem E. Paediatr Respir Rev. 2006;7 Suppl 1:S144-6. doi: 10.1016/j.prrv.2006.04.219. Epub 2006 Jun 5. Paediatr Respir Rev. 2006. PMID: 16798544 Review.
Treatment of cystic fibrosis in low-income countries.
Cohen-Cymberknoh M, Shoseyov D, Breuer O, Shamali M, Wilschanski M, Kerem E. Cohen-Cymberknoh M, et al. Among authors: kerem e. Lancet Respir Med. 2016 Feb;4(2):91-2. doi: 10.1016/S2213-2600(15)00507-X. Lancet Respir Med. 2016. PMID: 26868623 No abstract available.
Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis.
Cohen-Cymberknoh M, Gilead N, Gartner S, Rovira S, Blau H, Mussaffi H, Rivlin J, Gur M, Shteinberg M, Bentur L, Livnat G, Aviram M, Picard E, Tenenbaum A, Armoni S, Breuer O, Shoseyov D, Kerem E. Cohen-Cymberknoh M, et al. Among authors: kerem e. J Cyst Fibros. 2016 Nov;15(6):776-782. doi: 10.1016/j.jcf.2016.04.006. Epub 2016 May 1. J Cyst Fibros. 2016. PMID: 27143583 Free article.
Attention deficit hyperactivity disorder symptoms in patients with cystic fibrosis.
Cohen-Cymberknoh M, Tanny T, Breuer O, Blau H, Mussaffi H, Kadosh D, Gartner S, Salinas A, Bentur L, Nir V, Gur M, Reiter J, Shoseyov D, Kerem E, Berger I. Cohen-Cymberknoh M, et al. Among authors: kerem e. J Cyst Fibros. 2018 Mar;17(2):281-285. doi: 10.1016/j.jcf.2017.11.020. Epub 2017 Dec 19. J Cyst Fibros. 2018. PMID: 29269187 Free article.
Sleep disorders in cystic fibrosis: A systematic review and meta-analysis.
Reiter J, Gileles-Hillel A, Cohen-Cymberknoh M, Rosen D, Kerem E, Gozal D, Forno E. Reiter J, et al. Among authors: kerem e. Sleep Med Rev. 2020 Jun;51:101279. doi: 10.1016/j.smrv.2020.101279. Epub 2020 Feb 19. Sleep Med Rev. 2020. PMID: 32145647 Free PMC article.
Evidence of intestinal inflammation in patients with cystic fibrosis.
Werlin SL, Benuri-Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman J, Malka N, Cohen L, Armoni S, Yatzkan-Israelit Y, Bergwerk A, Aviram M, Bentur L, Mussaffi H, Bjarnasson I, Wilschanski M. Werlin SL, et al. Among authors: kerem e. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):304-8. doi: 10.1097/MPG.0b013e3181d1b013. J Pediatr Gastroenterol Nutr. 2010. PMID: 20512061
Genetic and electrophysiological characteristics of recurrent acute pancreatitis.
Werlin S, Konikoff FM, Halpern Z, Barkay O, Yerushalmi B, Broide E, Santo E, Shamir R, Shaoul R, Shteyer E, Yaakov Y, Cohen M, Kerem E, Ruszniewski P, Masson E, Ferec C, Wilschanski M. Werlin S, et al. Among authors: kerem e. J Pediatr Gastroenterol Nutr. 2015 May;60(5):675-9. doi: 10.1097/MPG.0000000000000623. J Pediatr Gastroenterol Nutr. 2015. PMID: 25383785
Equitable CF care as a basic human right.
De Boeck K, Kerem E. De Boeck K, et al. Among authors: kerem e. J Cyst Fibros. 2016 Nov;15(6):703-704. doi: 10.1016/j.jcf.2016.09.006. Epub 2016 Oct 15. J Cyst Fibros. 2016. PMID: 27751793 Free article. No abstract available.
Autosomal dominant gain of function STAT1 mutation and severe bronchiectasis.
Breuer O, Daum H, Cohen-Cymberknoh M, Unger S, Shoseyov D, Stepensky P, Keller B, Warnatz K, Kerem E. Breuer O, et al. Among authors: kerem e. Respir Med. 2017 May;126:39-45. doi: 10.1016/j.rmed.2017.03.018. Epub 2017 Mar 22. Respir Med. 2017. PMID: 28427548 Free article.
Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis children.
Orenti A, Pranke I, Faucon C, Varilh J, Hatton A, Golec A, Dehillotte C, Durieu I, Reix P, Burgel PR, Grenet D, Tasset C, Gachelin E, Perisson C, Lepissier A, Dreano E, Tondelier D, Chevalier B, Weiss L, Kiefer S, Laurans M, Chiron R, Lemonnier L, Marguet C, Jung A, Edelman A, Kerem BS, Girodon E, Taulan-Cadars M, Hinzpeter A, Kerem E, Naehrlich L, Sermet-Gaudelus I; ECFSPR Steering group. Orenti A, et al. Among authors: kerem e. J Cyst Fibros. 2023 Nov;22(6):1070-1079. doi: 10.1016/j.jcf.2023.06.005. Epub 2023 Jul 6. J Cyst Fibros. 2023. PMID: 37422433
Adrenal suppression in asthmatic children receiving low-dose inhaled budesonide: comparison between dry powder inhaler and pressurized metered-dose inhaler attached to a spacer.
Goldberg S, Einot T, Algur N, Schwartz S, Greenberg AC, Picard E, Virgilis D, Kerem E. Goldberg S, et al. Among authors: kerem e. Ann Allergy Asthma Immunol. 2002 Dec;89(6):566-71. doi: 10.1016/S1081-1206(10)62103-5. Ann Allergy Asthma Immunol. 2002. PMID: 12487221 Clinical Trial.
Mutation specific therapy in CF.
Kerem E. Kerem E. Paediatr Respir Rev. 2006;7 Suppl 1:S166-9. doi: 10.1016/j.prrv.2006.04.213. Epub 2006 Jun 5. Paediatr Respir Rev. 2006. PMID: 16798551 Review.
Treatment of sick children during low-intensity conflict.
Wexler ID, Branski D, Kerem E. Wexler ID, et al. Among authors: kerem e. Lancet. 2005 Apr 2-8;365(9466):1278-9. doi: 10.1016/S0140-6736(05)74818-2. Lancet. 2005. PMID: 15811463 No abstract available.
War and children.
Wexler ID, Branski D, Kerem E. Wexler ID, et al. Among authors: kerem e. JAMA. 2006 Aug 2;296(5):579-81. doi: 10.1001/jama.296.5.579. JAMA. 2006. PMID: 16882966 No abstract available.
Pregnancy and chronic progressive pulmonary disease.
Wexler ID, Johannesson M, Edenborough FP, Sufian BS, Kerem E. Wexler ID, et al. Among authors: kerem e. Am J Respir Crit Care Med. 2007 Feb 15;175(4):300-5. doi: 10.1164/rccm.200605-598OE. Epub 2006 Nov 16. Am J Respir Crit Care Med. 2007. PMID: 17110647 Review.
Early intervention in CF: how to monitor the effect.
Weiser G, Kerem E. Weiser G, et al. Among authors: kerem e. Pediatr Pulmonol. 2007 Nov;42(11):1002-7. doi: 10.1002/ppul.20718. Pediatr Pulmonol. 2007. PMID: 17893918 Review.
Influenza A infection in young infants.
Rekhtman D, Wolf DG, Levy-Khademi F, Averbuch D, Kerem E, Wexler ID. Rekhtman D, et al. Among authors: kerem e. Arch Dis Child. 2011 Nov;96(11):1085-7. doi: 10.1136/adc.2010.182873. Epub 2010 Oct 27. Arch Dis Child. 2011. PMID: 21030378
268 results